Baraldi M
School of Pharmacy, Department of Pharmaceutical Sciences, Modena University, Italy.
Neurochem Res. 1990 Feb;15(2):153-60. doi: 10.1007/BF00972205.
During the past decade a new approach to pathogenetic studies of hepatic encephalopathy has been undertaken to identify the neurochemical alterations which characterize the syndrome. Using animal models of hepatic encephalopathy electrophysiological, behavioral, pharmacological and biochemical evidence were provided of an increased functional activity of the GABA-A receptors, including the Benzodiazepine site. These demonstrations seem to explain the increased sensitivity of patients with acute or chronic liver disease to sedative administration. The described increased tone of the GABAergic receptor complex seems to play a key role in the generalized depression of the central nervous system which characterizes hepatic encephalopathy, but other factors seem to contribute to the neuronal derangement present in this syndrome leading to an imbalance between inhibitory and excitatory receptor systems in the brain. Based on these findings a new symptomatic treatment with anti-benzodiazepine compounds which seem temporarily to counteract the symptoms of hepatic encephalopathy, was introduced.
在过去十年中,人们采用了一种新的肝性脑病发病机制研究方法,以确定该综合征所特有的神经化学改变。利用肝性脑病动物模型,电生理、行为、药理学和生物化学证据表明,包括苯二氮䓬位点在内的GABA-A受体功能活性增强。这些证据似乎可以解释急性或慢性肝病患者对镇静剂给药的敏感性增加。所描述的GABA能受体复合物张力增加似乎在肝性脑病所特有的中枢神经系统普遍抑制中起关键作用,但其他因素似乎也导致了该综合征中存在的神经元紊乱,从而导致大脑中抑制性和兴奋性受体系统失衡。基于这些发现,引入了一种新的对症治疗方法,即使用抗苯二氮䓬化合物,这种化合物似乎可以暂时抵消肝性脑病的症状。